Paper Details

  1. Home
  2. Paper Details

Pediatric Population Pharmacokinetic Modeling and Exposure-Response Analysis of Ambrisentan in Pulmonary Arterial Hypertension and Comparison With Adult Data.

Author: BeeraheeMisba, BeghettiMaurice, FarrellColm, LukasMary Ann, OkourMalek, ThaparMita M

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study developed a population pharmacokinetic (PK) model for ambrisentan in pediatric patients with pulmonary arterial hypertension (PAH). The model showed that ambrisentan exposure in children was similar to adults when adjusting for body weight. There was no clear association between ambrisentan exposure and efficacy (6-minute walking distance) or safety (adverse events) in either pediatric or adult populations. These findings suggest that body-weight-based dosing of ambrisentan is appropriate for children with PAH.
Paper Details　
Original Abstract of the Article :
This study aimed to develop a population pharmacokinetic (PK) model of ambrisentan in pediatric patients (8 to <18 years) with pulmonary arterial hypertension (PAH) and compare pediatric ambrisentan systemic exposure with previously reported adult data. Association of ambrisentan exposure with effic...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/jcph.2199

データ提供：米国国立医学図書館（NLM）

A Tailor-Made Approach to Pediatric Pulmonary Arterial Hypertension

The world of [pulmonary arterial hypertension (PAH)] is a complex and challenging landscape, especially for pediatric patients. This study, like a skilled cartographer, maps out the pharmacokinetics of [ambrisentan], a PAH treatment, in pediatric patients. The researchers developed a [population pharmacokinetic (PK) model] to understand how ambrisentan is absorbed, distributed, metabolized, and eliminated in children. They then compared the results to previously reported adult data, looking for similarities and differences in drug exposure.

Their findings, like a treasure map revealing hidden pathways, show that ambrisentan exposure in pediatric patients is similar to that in adults when accounting for body weight differences. This suggests that body-weight-based dosing may be an effective strategy for managing PAH in children.

Navigating the Landscape of Pediatric PAH Treatment

This study provides valuable insights into the pharmacokinetics of ambrisentan in pediatric patients. This information is crucial for developing appropriate dosing strategies and ensuring safe and effective treatment.

From Map to Reality: Personalized Treatment for PAH

The study emphasizes the importance of personalized medicine in managing PAH. By understanding the unique pharmacokinetic profiles of individual patients, we can optimize drug dosage and minimize potential adverse effects. This research represents a significant step forward in providing effective and safe treatment options for children with PAH.

Dr. Camel's Conclusion

This research sheds light on the pharmacokinetics of ambrisentan in pediatric patients, highlighting the importance of body-weight-based dosing for effective treatment. It underscores the significance of personalized medicine in managing complex conditions like PAH, ensuring safe and effective care for all patients.

Date :
  1. Date Completed 2023-04-12
  2. Date Revised 2023-06-01
Further Info :

Pubmed ID

36579617

DOI: Digital Object Identifier

10.1002/jcph.2199

Related Literature

Article Analysis
・Effects of ambrisentan
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.